Why Mesoblast shares could rise 40% in a year

This biotech could be high risk, high reward picks according to Bell Potter. The post Why Mesoblast shares could rise 40% in ...

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) ...